Please try another search
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Name | Age | Since | Title |
---|---|---|---|
David Lionel Brookes | 63 | 2019 | Executive Chairman |
Peter Gibson | - | 2018 | Chairman of Product Development Advisory Board |
Rebecca Burgell | - | 2018 | Member of Product Development Advisory Board |
Barry Campbell | - | 2018 | Member of Product Development Advisory Board |
Nicholas Haslam | - | 2022 | Non-Executive Director |
Jakob Begun | - | 2018 | Member of Product Development Advisory Board |
Simon Keely | - | 2018 | Member of Product Development Advisory Board |
John Michailidis | - | 2022 | COO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review